2018 Physicians Safety 
Referral MD
OCTOBER 23, 2024
A patient’s physician or healthcare provider can decide what treatment the patient needs. Patient safety Patient safety is paramount. Level three: If still unsatisfactory, the appeal may go to a neutral party, often a physician with a similar specialty as the appealing doctor. What is prior authorization?
World of DTC Marketing
AUGUST 12, 2022
Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 12, 2023
The drug is being developed by AstraZeneca and Avillion under a co-development agreement signed in March 2018. Physicians will be able to offer their patients Airsupra, an important new rescue treatment that reduces the risk of asthma exacerbations.”.
Pharmaceutical Technology
MARCH 24, 2023
For example, the cost of Humira biosimilars in Denmark decreased by 82% from September 2018 to December 2018. Further, there remains scepticism on the efficacy and safety of biosimilars. Since Humira biosimilars entered Europe, they have been noted to cause steep discounts in price, higher uptake, and big cost savings.
European Pharmaceutical Review
MAY 20, 2024
5,6 Clinical trials are essential for the safety and efficacy of novel therapies to be established. 8 Using RWE in rare disease drug development: effective innovations with historical controls Standard clinical trial designs are not always appropriate for diseases with small patient populations to generate adequate safety and efficacy data.
European Pharmaceutical Review
SEPTEMBER 21, 2023
Considerable progress has been made in other areas including enhancing safety, improving treatment administration and patient monitoring systems and implementing innovative pricing strategies – all with the goal of providing timely access to eligible patients who can benefit from these treatments. Available from: [link]. Anguela XM, High KA.
European Pharmaceutical Review
MARCH 4, 2024
Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Dave Li, PhD Dave Li is a principal consultant and Clinical Research Physician with KCR. References 1. cited 2024Jan].
Expert insights. Personalized for you.
102 
Let's personalize your content